Novel heterocyclic compounds of formula I:A-B-D Formula Ior a pharmaceutically acceptable salt thereof,wherein: A is selected from the group consisting of a moiety having general Formula II and a moiety having general Formula III:B is a moiety selected from the group consisting of:D is a moiety selected from the group consisting of:which exhibit a dopamine receptor (preferably a D4 receptor) and/or a serotonine receptor (preferably 5HTA1 agonistic activity), processes of preparing same, pharmaceutical compositions containing same and uses thereof in the treatment of medical conditions associated with the dopaminergic and/or serotonergic systems (e.g., sexual disorders, dyskinesia, anxiety) are disclosed.
